Human Monocyte-Derived Dendritic Cells Are the Pharmacological Target of the Immunosuppressant Flavonoid Silibinin

Int J Mol Sci. 2022 Sep 8;23(18):10417. doi: 10.3390/ijms231810417.

Abstract

Silibinin, a natural polyphenolic flavonoid, is known to possess anti-inflammatory, anticancer, antioxidant, and immunomodulatory properties. However, the effects of Silibinin on the maturation and immunostimulatory functions of human dendritic cells (DC) remain to be elucidated. In this study, we have attempted to ascertain whether Silibinin influences the maturation, cytokine production, and antigen-presenting capacity of human monocyte-derived DC. We show that Silibinin significantly suppresses the upregulation of costimulatory and MHC molecules in LPS-stimulated mature DC and inhibits lipopolysaccharide (LPS)-induced interleukin (IL)-12, IL-23, and TNF-α production. Furthermore, Silibinin impairs the proliferation response of the allogenic memory CD4 T lymphocytes elicited by LPS-matured DC and their Th1/Th17 profile. These findings demonstrate that Silibinin displays immunosuppressive activity by inhibiting the maturation and activation of human DC and support its potential application of adjuvant therapy in the treatment of autoimmune diseases.

Keywords: autoimmunity; dendritic cells; immunosuppression.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / pharmacology
  • Cell Differentiation
  • Cells, Cultured
  • Cytokines / pharmacology
  • Dendritic Cells
  • Flavonoids / pharmacology
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Interleukin-12
  • Interleukin-23
  • Lipopolysaccharides* / pharmacology
  • Monocytes*
  • Silybin / pharmacology
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Cytokines
  • Flavonoids
  • Immunosuppressive Agents
  • Interleukin-23
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • Silybin

Grants and funding

This research received no external funding.